Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel Sells 5,574 Shares

Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel sold 5,574 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $304,228.92. Following the sale, the chief executive officer now directly owns 154,828 shares of the company’s stock, valued at approximately $8,450,512.24. This trade represents a 3.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Disc Medicine Stock Performance

Shares of NASDAQ IRON opened at $54.35 on Friday. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60. The firm has a 50 day moving average price of $59.26 and a two-hundred day moving average price of $55.02.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC boosted its stake in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after purchasing an additional 503 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Disc Medicine in the 4th quarter valued at $40,000. Tower Research Capital LLC TRC boosted its stake in shares of Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after purchasing an additional 266 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after purchasing an additional 337 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Disc Medicine in the 3rd quarter valued at $131,000. 83.70% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on IRON shares. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $66.00 to $110.00 in a report on Monday, November 4th. Scotiabank upped their price objective on shares of Disc Medicine from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Wedbush reiterated an “outperform” rating and set a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Finally, Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a research report on Tuesday, November 5th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $88.90.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.